Xanomeline/Trospium (Cobenfy) for Schizophrenia
Xanomeline/Trospium (Cobenfy) for Schizophrenia
November 11, 2024 (Issue: 1715)
The FDA has approved Cobenfy (BMS), an oral
fixed-dose combination of the muscarinic agonist
xanomeline and the peripheral muscarinic antagonist
trospium chloride, for treatment of schizophrenia in
adults. It is the first antipsychotic drug to be...more
- I Kaul et al. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial. Lancet 2024; 403:160. doi:10.1016/s0140-6736(23)02190-6
- I Kaul et al. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial. JAMA Psychiatry 2024; 81:749. doi:10.1001/jamapsychiatry.2024.0785
- I Kaul et al. Maintenance of efficacy of KarXT (xanomeline and trospium) in schizophrenia. Abstract F264. 2024 Annual Congress of the Schizophrenia International Research Society (SIRS); Florence, Italy; April 3-7, 2024.
- R Marcus et al. Long-term safety of KarXT (xanomeline and trospium) in schizophrenia. Abstract F74. 2024 Annual Congress of the Schizophrenia International Research Society (SIRS); Florence, Italy; April 3-7, 2024.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. October 5, 2024. Reprinted with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Xanomeline/Trospium (Cobenfy) for Schizophrenia
Article code: 1715a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
